Corbus Pharma (CRBP) Advances to Session High, Up 33%
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Corbus Pharma (NASDAQ: CRBP) hit session highs heading into mid-day, extending gains after Cantor initiated coverage on the stock with a Buy rating and a price target of $17.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Corbus Pharma (CRBP) Mentioned Cautiously by Adam Feuerstein
- Cantor Fitzgerald Defends Corbus Pharmaceuticals (CRBP) Following Short Report
- ContraVir Pharma (CTRV) Gains on Heavy Volume